{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T14:46:39Z","timestamp":1790433999785,"version":"4.1.0"},"reference-count":125,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["5R21MH103717"],"award-info":[{"award-number":["5R21MH103717"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.euroneuro.2018.12.014","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T02:12:30Z","timestamp":1546999950000},"page":"330-348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["A systematic review of phytocannabinoid exposure on the endocannabinoid system: Implications for psychosis"],"prefix":"10.1016","volume":"29","author":[{"given":"Maya R.","family":"Jacobson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy J.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Boileau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junchao","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina","family":"Mizrahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2018.12.014_bib0001","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S0140-6736(87)92620-1","article-title":"Cannabis and schizophrenia. A longitudinal study of Swedish conscripts","volume":"2","author":"Andreasson","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0002","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1136\/bmj.325.7374.1212","article-title":"Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study","volume":"325","author":"Arseneault","year":"2002","journal-title":"B.M.J."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0003","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/157015907780866910","article-title":"Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity","volume":"5","author":"Basavarajappa","year":"2007","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0004","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1097\/00001756-200004270-00018","article-title":"Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol","volume":"11","author":"Beltramo","year":"2000","journal-title":"Neuroreport"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0005","doi-asserted-by":"crossref","first-page":"19115","DOI":"10.1073\/pnas.0509494102","article-title":"Endocannabinoids regulate interneuron migration and morphogenesis by transactivating the TrkB receptor","volume":"102","author":"Berghuis","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0006","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1126\/science.1137406","article-title":"Hardwiring the brain: endocannabinoids shape neuronal connectivity","volume":"316","author":"Berghuis","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0007","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1038\/npp.2013.165","article-title":"Peripheral endocannabinoid system dysregulation in first-episode psychosis","volume":"38","author":"Bioque","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0180","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","article-title":"Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake andenzymatic hydrolysis of anandamide","volume":"134","author":"Bisogno","year":"2001","journal-title":"Br J Pharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2018.12.014_bib0008","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/npp.2017.209","article-title":"Clinical and pre-clinical evidence for functional interactions of cannabidiol and delta9-tetrahydrocannabinol","volume":"43","author":"Boggs","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0009","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.biopsych.2016.04.012","article-title":"Fatty acid amide hydrolase binding in brain of cannabis users: imaging with the novel radiotracer [11C]CURB","volume":"80","author":"Boileau","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0010","doi-asserted-by":"crossref","DOI":"10.1093\/schbul\/sby017.711","article-title":"Cannabinoid 1 receptor availability & memory function in first episode psychosis: a multi-modal pet-fMRI study","volume":"44,","author":"Borgan","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0011","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0006-2952(94)90236-4","article-title":"Induction and genetic regulation of mouse hepatic cytochrome P450 by cannabidiol","volume":"48","author":"Bornheim","year":"1994","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0012","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.pneurobio.2010.06.010","article-title":"Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia","volume":"92","author":"Bossong","year":"2010","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0014","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/sj.bjp.0707481","article-title":"Novel cannabinoid receptors","volume":"152","author":"Brown","year":"2007","journal-title":"Br. J. Pharmacol"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0015","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1038\/npp.2017.50","article-title":"The differential binding of antipsychotic drugs to the ABC transporter P-glycoprotein predicts cannabinoid-antipsychotic drug interactions","volume":"42","author":"Brzozowska","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0016","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1476-5381.2010.00787.x","article-title":"Quantification of brain endocannabinoid levels: methods, interpretations and pitfalls","volume":"160","author":"Buczynski","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0017","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/bmj.323.7303.13","article-title":"Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review","volume":"323","author":"Campbell","year":"2001","journal-title":"B.M.J."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0018","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.neuroimage.2013.04.052","article-title":"Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia","volume":"79","author":"Ceccarini","year":"2013","journal-title":"Neuroimage"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0019","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/adb.12116","article-title":"[18F]MK-9470 PET measurement of cannabinoid CB1 receptor availability in chronic cannabis users","volume":"20","author":"Ceccarini","year":"2015","journal-title":"Addict. Biol."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0020","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S2215-0366(16)30208-5","article-title":"Marijuana use and use disorders in adults in the USA, 2002\u201314: analysis of annual cross-sectional surveys","volume":"3","author":"Compton","year":"2016","journal-title":"Lancet Psychiatr."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0021","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1111\/bph.12746","article-title":"Activation of GPR18 by cannabinoid compounds: a tale of biased agonism","volume":"171","author":"Console-Bram","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0022","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.lfs.2012.06.009","article-title":"Sex differences in cannabinoid pharmacology: a reflection of differences in the endocannabinoid system?","volume":"92","author":"Craft","year":"2013","journal-title":"Life. Sci."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0023","doi-asserted-by":"crossref","first-page":"10821","DOI":"10.1073\/pnas.0401292101","article-title":"Functional disassociation of the central and peripheral fatty acid amide signaling systems","volume":"101","author":"Cravatt","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0024","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00213-002-1169-0","article-title":"Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users","volume":"164","author":"Curran","year":"2002","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0025","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.biopsych.2004.12.006","article-title":"Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction","volume":"57","author":"D'Souza","year":"2005","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0026","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bpsc.2015.09.008","article-title":"Rapid changes in CB1 receptor availability in cannabis dependent males after abstinence from cannabis","volume":"1","author":"D'Souza","year":"2016","journal-title":"Biol. Psychiatr. Cogn. Neurosci. Neuroimaging"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0027","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/sj.npp.1300496","article-title":"The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis","volume":"29","author":"D'Souza","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0028","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0306-4522(00)00552-2","article-title":"Studies on [H-3]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use","volume":"103","author":"Dean","year":"2001","journal-title":"Neuroscience"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0029","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3389\/fpsyt.2012.00085","article-title":"Plasma endocannabinoid alterations in individuals with substance use disorder are dependent on the \u201cMirror Effect\u201d of schizophrenia","volume":"3","author":"Desfoss\u00e9s","year":"2012","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0030","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S2215-0366(14)00117-5","article-title":"Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study","volume":"2","author":"Di Forti","year":"2015","journal-title":"Lancet Psychiatr."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0031","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0166-2236(98)01283-1","article-title":"Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action","volume":"21","author":"Di Marzo","year":"1998","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0032","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1530\/EJE-09-0643","article-title":"Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects","volume":"161","author":"Di Marzo","year":"2009","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0033","doi-asserted-by":"crossref","first-page":"6395","DOI":"10.1038\/ncomms7395","article-title":"FAAH genetic variation enhances fronto-amygdala function in mouse and human","volume":"6","author":"Dincheva","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0034","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/archpsyc.65.7.772","article-title":"Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia","volume":"65","author":"Eggan","year":"2008","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0035","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1038\/npp.2010.75","article-title":"Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: comparison of schizophrenia and major depressive disorder","volume":"35","author":"Eggan","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0036","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1191\/0960327104ht426oa","article-title":"Effect of cannabinoid ingestion (in the form of bhang) on the immune system of high school and university students","volume":"23","author":"El-Gohary","year":"2004","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0037","doi-asserted-by":"crossref","first-page":"8711","DOI":"10.1074\/jbc.M114.618447","article-title":"Fatty acid-binding proteins (FABPs) are intracellular carriers for Delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD)","volume":"290","author":"Elmes","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0038","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.biopsych.2016.01.004","article-title":"Changes in cannabis potency over the last 2 decades (1995\u20132014): analysis of current data in the United States","volume":"79","author":"ElSohly","year":"2016","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0039","series-title":"European Drug Report 2018: Trends and Developments","year":"2018"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0040","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.2337\/diabetes.54.10.2838","article-title":"Activation of the peripheral endocannabinoid system in human obesity","volume":"54","author":"Engeli","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0041","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s11920-012-0284-9","article-title":"Clinically significant psychotropic drug-drug interactions in the primary care setting","volume":"14","author":"English","year":"2012","journal-title":"Curr. Psychiatry. Rep."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0042","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s12035-016-9697-5","article-title":"Role of the endocannabinoid system in the pathophysiology of schizophrenia","volume":"54","author":"Fakhoury","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0043","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0166-2236(99)01491-5","article-title":"The endogenous cannabinoid system and brain development","volume":"23","author":"Fernandez-Ruiz","year":"2001","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0044","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.tips.2016.12.003","article-title":"Synthetic pot: not your grandfather's marijuana","volume":"38","author":"Ford","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0045","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0006-2952(01)00712-2","article-title":"Fatty acid amide hydrolase: biochemistry, pharmacology, and therapeutic possibilities for an enzyme hydrolyzing anandamide, 2-arachidonoylglycerol, palmitoylethanolamide, and oleamide","volume":"62","author":"Fowler","year":"2001","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0046","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000339075","article-title":"Type-1 cannabinoid receptor signaling in neuronal development","volume":"90","author":"Gaffuri","year":"2012","journal-title":"Pharmacology"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0047","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1432-1033.1995.tb20780.x","article-title":"Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations","volume":"232","author":"Galiegue","year":"1995","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0048","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3389\/fpsyt.2015.00041","article-title":"Role of the endogenous cannabinoid system in nicotine addiction: novel insights","volume":"6","author":"Gamaleddin","year":"2015","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0049","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1038\/sj.npp.1300558","article-title":"Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms","volume":"29","author":"Giuffrida","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0050","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0006-8993(02)03344-9","article-title":"Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine","volume":"954","author":"Gonzalez","year":"2002","journal-title":"Brain Res"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0051","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1460-9568.2004.03428.x","article-title":"Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala","volume":"20","author":"Gulyas","year":"2004","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0052","doi-asserted-by":"crossref","first-page":"653","DOI":"10.5665\/sleep.5546","article-title":"Sleep restriction enhances the daily rhythm of circulating levels of endocannabinoid 2-arachidonoylglycerol","volume":"39","author":"Hanlon","year":"2016","journal-title":"Sleep"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0053","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1073\/pnas.87.5.1932","article-title":"Cannabinoid receptor localization in brain","volume":"87","author":"Herkenham","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0054","doi-asserted-by":"crossref","DOI":"10.1093\/schbul\/sby014.177","article-title":"The endocannabinoid system in first-episode psychosis","volume":"44,","author":"Hietala","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0055","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/npp.2017.130","article-title":"Circulating endocannabinoids: from whence do they come and where are they going?","volume":"43","author":"Hillard","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0056","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/mp.2011.82","article-title":"Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers","volume":"17","author":"Hirvonen","year":"2012","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0057","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00259-010-1426-0","article-title":"Approaches to quantify radioligands that wash out slowly from target organs","volume":"37","author":"Hirvonen","year":"2010","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0058","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1124\/pr.54.2.161","article-title":"International Union of Pharmacology. XXVII. Classification of cannabinoid receptors","volume":"54","author":"Howlett","year":"2002","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0059","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00213-007-0861-5","article-title":"Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users","volume":"194","author":"Huestis","year":"2007","journal-title":"Psychopharmacology (Berl.)."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0060","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1001\/archpsyc.58.4.322","article-title":"Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716","volume":"58","author":"Huestis","year":"2001","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0061","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2133\/dmpk.DMPK-12-RG-129","article-title":"Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19","volume":"28","author":"Jiang","year":"2013","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0062","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.lfs.2011.05.018","article-title":"Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes","volume":"89","author":"Jiang","year":"2011","journal-title":"Life Sci."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0063","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/nm.f.1869","article-title":"Endocannabinoid signaling as a synaptic circuit breaker in neurological disease","volume":"14","author":"Katona","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0064","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s40263-013-0114-6","article-title":"Clinically significant drug interactions with atypical antipsychotics","volume":"27","author":"Kennedy","year":"2013","journal-title":"C.N.S. Drugs"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0065","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/schbul\/sbt141","article-title":"Inflammation and schizophrenia","volume":"39","author":"Kirkpatrick","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0066","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1192\/bjp.bp.108.053843","article-title":"Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis","volume":"194","author":"Koethe","year":"2009","journal-title":"Br. J. Psychiatr."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0067","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/schbul\/sbp031","article-title":"Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis","volume":"36","author":"Koskinen","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0068","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1111\/bph.13724","article-title":"Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders","volume":"174","author":"Lee","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0069","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2007.04.025","article-title":"Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use","volume":"94","author":"Leweke","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0070","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl. Psychiatr."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0071","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s11481-015-9600-6","article-title":"Cannabinoids for the treatment of chronic non-cancer pain: an updated systematic review of randomized controlled trials","volume":"10","author":"Lynch","year":"2015","journal-title":"J. Neuroimmune. Pharmacol."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0072","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/3-540-26573-2_10","article-title":"Distribution of cannabinoid receptors in the central and peripheral nervous system","volume":"168","author":"Mackie","year":"2005","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0073","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/ADM.0000000000000118","article-title":"Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans","volume":"9","author":"Manini","year":"2015","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0074","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/schbul\/sbw003","article-title":"Meta-analysis of the association between the level of cannabis use and risk of psychosis","volume":"42","author":"Marconi","year":"2016","journal-title":"Schizophr. Bull."},{"issue":"Suppl 1","key":"10.1016\/j.euroneuro.2018.12.014_bib0075","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1038\/sj.ijo.0803271","article-title":"Endogenous cannabinoids in the brain and peripheral tissues: regulation of their levels and control of food intake","volume":"30","author":"Matias","year":"2006","journal-title":"Int. J. Obes. (Lond.)"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0076","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/346561a0","article-title":"Structure of a cannabinoid receptor and functional expression of the cloned cDNA","volume":"346","author":"Matsuda","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0077","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/0024-3205(95)00193-A","article-title":"Metabolism of delta 9-tetrahydrocannabinol by cytochrome P450 isozymes purified from hepatic microsomes of monkeys","volume":"56","author":"Matsunaga","year":"1995","journal-title":"Life Sci."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0078","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(07)61162-3","article-title":"Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review","volume":"370","author":"Moore","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0079","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1192\/bjp.bp.112.121178","article-title":"Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms","volume":"202","author":"Morgan","year":"2013","journal-title":"Br. J. Psychiatr."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0080","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00210-014-0984-2","article-title":"Increased CB2 mRNA and anandamide in human blood after cessation of cannabis abuse","volume":"387","author":"Muhl","year":"2014","journal-title":"N.S. Arch. Pharmacol."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0081","doi-asserted-by":"crossref","first-page":"8760","DOI":"10.1073\/pnas.0803545105","article-title":"Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning","volume":"105","author":"Mulder","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0082","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1586\/14737175.8.7.1037","article-title":"Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia","volume":"8","author":"Muller-Vahl","year":"2008","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0083","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/01.ftd.0000197091.07807.22","article-title":"Review of biologic matrices (urine, blood, hair) as indicators of recent or ongoing cannabis use","volume":"28","author":"Musshoff","year":"2006","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0084","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/0-306-47611-8_27","article-title":"CB1 and CB2 receptor mRNA expression in human peripheral blood mononuclear cells (PBMC) from various donor types","volume":"493","author":"Nong","year":"2001","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0085","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/jcbfm.2015.46","article-title":"Imaging the cannabinoid CB1 receptor in humans with [11C]OMAR: assessment of kinetic analysis methods, test-retest reproducibility, and gender differences","volume":"35","author":"Normandin","year":"2015","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0086","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/08998280.2000.11927719","article-title":"Drug interactions due to cytochrome P450","volume":"13","author":"Ogu","year":"2000","journal-title":"Proc. (Bayl. Univ. Med. Cent.)"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0087","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1196\/annals.1369.052","article-title":"Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain","volume":"1074","author":"Onaivi","year":"2006","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0088","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.phrs.2009.03.019","article-title":"Endocannabinoids and immune regulation","volume":"60","author":"Pandey","year":"2009","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0089","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.pharmthera.2013.01.003","article-title":"Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction","volume":"138","author":"Panlilio","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0090","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrn4004","article-title":"Endocannabinoid signalling in reward and addiction","volume":"16","author":"Parsons","year":"2015","journal-title":"Nat. Rev. Neurosci."},{"issue":"Suppl 1","key":"10.1016\/j.euroneuro.2018.12.014_bib0091","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1038\/sj.bjp.0706406","article-title":"Cannabinoid pharmacology: the first 66 years","volume":"147","author":"Pertwee","year":"2006","journal-title":"Br. J. Pharmacol."},{"issue":"Suppl 1","key":"10.1016\/j.euroneuro.2018.12.014_bib0092","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1038\/sj.ijo.0803272","article-title":"The pharmacology of cannabinoid receptors and their ligands: an overview","volume":"30","author":"Pertwee","year":"2006","journal-title":"Int. J. Obes. (Lond.)"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0093","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1369-1600.2008.00108.x","article-title":"Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond","volume":"13","author":"Pertwee","year":"2008","journal-title":"Addict. Biol."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0094","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0014-2999(02)02624-9","article-title":"(-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens","volume":"456","author":"Pertwee","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0095","doi-asserted-by":"crossref","first-page":"PL1","DOI":"10.1016\/S0024-3205(98)00238-0","article-title":"Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors","volume":"63","author":"Petitet","year":"1998","journal-title":"Life Sci."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0096","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1177\/0269881107083816","article-title":"Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy","volume":"22","author":"Potvin","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0097","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0924-977X(98)00040-6","article-title":"Drug metabolism and atypical antipsychotics","volume":"9","author":"Prior","year":"1999","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0098","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3389\/fpsyt.2014.00054","article-title":"Gone to pot \u2013 a review of the association between cannabis and psychosis","volume":"5","author":"Radhakrishnan","year":"2014","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0099","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.biopsych.2015.08.021","article-title":"Reduced brain cannabinoid receptor availability in schizophrenia","volume":"79","author":"Ranganathan","year":"2016","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0100","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000338642","article-title":"CB1 and CB2 receptor expression and promoter methylation in patients with cannabis dependence","volume":"19","author":"Rotter","year":"2013","journal-title":"Eur Addict. Res."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0101","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/0269881111408958","article-title":"The endocannabinoid system in anxiety, fear memory and habituation","volume":"26","author":"Ruehle","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0102","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s00259-009-1340-5","article-title":"Kinetic analysis of the cannabinoid-1 receptor PET tracer [(18)F]MK-9470 in human brain","volume":"37","author":"Sanabria-Bohorquez","year":"2010","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0103","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00213-015-4196-3","article-title":"Interactions between the endocannabinoid and nicotinic cholinergic systems: preclinical evidence and therapeutic perspectives","volume":"233","author":"Scherma","year":"2016","journal-title":"Psychopharmacology (Berl.)."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0104","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1369-1600.2008.00110.x","article-title":"Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure","volume":"13","author":"Schneider","year":"2008","journal-title":"Addict. Biol."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0105","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1360-0443.2010.03228.x","article-title":"Differentiating new cannabis use from residual urinary cannabinoid excretion in chronic, daily cannabis users","volume":"106","author":"Schwilke","year":"2011","journal-title":"Addiction"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0106","doi-asserted-by":"crossref","first-page":"e920","DOI":"10.1038\/tp.2016.195","article-title":"Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose","volume":"6","author":"Seeman","year":"2016","journal-title":"Transl. Psychiatr."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0107","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nature08186","article-title":"Common variants conferring risk of schizophrenia","volume":"460","author":"Stefansson","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0108","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/03602532.2013.849268","article-title":"Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review","volume":"46","author":"Stout","year":"2014","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0109","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/7854_2016_60","article-title":"Pharmacological and toxicological effects of synthetic cannabinoids and their metabolites","volume":"32","author":"Tai","year":"2017","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0110","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/dta.1561","article-title":"Quantification of anandamide and 2-arachidonoylglycerol plasma levels to examine potential influences of tetrahydrocannabinol application on the endocannabinoid system in humans","volume":"6","author":"Thieme","year":"2014","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0111","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/sj.bjp.0707133","article-title":"Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro","volume":"150","author":"Thomas","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0112","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/ajmg.b.30491","article-title":"The fatty acid amide hydrolase C385A (P129T) missense variant in cannabis users: studies of drug use and dependence in Caucasians","volume":"144B","author":"Tyndale","year":"2007","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0113","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1111\/febs.12152","article-title":"Metabolism of endocannabinoids and related N-acylethanolamines: canonical and alternative pathways","volume":"280","author":"Ueda","year":"2013","journal-title":"FEBS. J."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0200","unstructured":"United Nations Office on Drug and Crime (2018). World Drug Report 2018, United Nations publication, Sales No. E.18.XI.9. Retrieved from https:\/\/www.unodc.org\/wdr2018\/prelaunch\/WDR18_Booklet_1_EXSUM.pdf."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0114","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2174\/138920008784746373","article-title":"Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions","volume":"9","author":"Urichuk","year":"2008","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0115","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.neuroimage.2007.10.053","article-title":"Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [(18)F]MK-9470 PET","volume":"39","author":"Van Laere","year":"2008","journal-title":"Neuroimage"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0116","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1126\/science.1115740","article-title":"Identification and functional characterization of brainstem cannabinoid CB2 receptors","volume":"310","author":"Van Sickle","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0117","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.neuroscience.2006.11.012","article-title":"Chronic use of marijuana decreases cannabinoid receptor binding and mRNA expression in the human brain","volume":"145","author":"Villares","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0118","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.schres.2014.07.017","article-title":"Reciprocal alterations in cortical cannabinoid receptor 1 binding relative to protein immunoreactivity and transcript levels in schizophrenia","volume":"159","author":"Volk","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0119","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.schres.2013.02.038","article-title":"Endocannabinoid metabolism in the prefrontal cortex in schizophrenia","volume":"147","author":"Volk","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0120","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/JCP.0b013e3182984015","article-title":"Exogenous delta(9)-tetrahydrocannabinol influences circulating endogenous cannabinoids in humans","volume":"33","author":"Walter","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0121","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1248\/bpb.19.1109","article-title":"Inhibition of anandamide amidase activity in mouse brain microsomes by cannabinoids","volume":"19","author":"Watanabe","year":"1996","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0122","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.neuroimage.2010.04.197","article-title":"Cannaboid CB1 receptor imaging in vivo in schizophrenia by positron emission tomography","volume":"52","author":"Wong","year":"2010","journal-title":"Neuroimage"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0123","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/S0140-6736(03)14738-1","article-title":"Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial","volume":"362","author":"Zajicek","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2018.12.014_bib0124","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.pnpbp.2003.11.005","article-title":"Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia","volume":"28","author":"Zavitsanou","year":"2004","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatr."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X18320054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X18320054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T01:45:31Z","timestamp":1606009531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X18320054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":125,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0924977X18320054"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2018.12.014","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review of phytocannabinoid exposure on the endocannabinoid system: Implications for psychosis","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2018.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}